EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer

Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, Aranka Brockmueller, Mehdi Shakibaei, Dietrich Büsselberg

Cancer and Metastasis Reviews · 2024-12 · 43 (4) · 1297-1314

DOI: 10.1007/s10555-024-10192-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, online erschienen am 27.05.2024. Verfasst von Shahad Sabaawi Ibrahim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, 24144, Qatar. Hauptthemen laut MEDLINE: Obesity, Neoplasms, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Research Fund, Weill Cornell Medical College in Qatar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityNeoplasmsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHumansAnimalsHypoglycemic Agents

Stichwörter der Autor:innen

CancerDiabetesGLP1RAObesityOzempicSemaglutide

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, 24144, Qatar.
  • Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Pettenkoferstr. 11, D-80336, Munich, Germany.
  • Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, 24144, Qatar. dib2015@qatar-med.cornell.edu.

Förderung

  • Qatar National Research Fund
  • Weill Cornell Medical College in Qatar

Zitieren

APA

Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024). The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer and Metastasis Reviews, 43(4), 1297-1314. https://doi.org/10.1007/s10555-024-10192-9

Vancouver

Ibrahim SS, Ibrahim RS, Arabi B, Brockmueller A, Shakibaei M, Büsselberg D. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer and Metastasis Reviews. 2024;43(4):1297-1314. doi:10.1007/s10555-024-10192-9

BibTeX
@article{Ibrahim2024,
  author = {Ibrahim, Shahad Sabaawi and Ibrahim, Raghad Sabaawi and Arabi, Batoul and Brockmueller, Aranka and Shakibaei, Mehdi and Büsselberg, Dietrich},
  title = {The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer},
  journal = {Cancer and Metastasis Reviews},
  year = {2024},
  volume = {43},
  number = {4},
  pages = {1297--1314},
  doi = {10.1007/s10555-024-10192-9}
}
Kostenlos starten →